Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings

Cancer

Volumn 86, Issue 1, 1999, Pages 64-71

  Hickok, Jane T ^a   Roscoe, Joseph A ^a   Morrow, Gary R ^a   Stern, Robert M ^b   Yang, Bo ^a   Flynn, Patrick J ^c   Hynes, Harry E ^d   Kirshner, Jeffrey J ^e   Rosenbluth, Richard J ^f  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Metro Minnesota Community Clinical Oncology Program   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e Syracuse Hematol Oncol Comm C   (United States)

^f Northern New Jersey Cancer Center   (United States)

Author keywords

5 HT3 receptor antagonists; Breast carcinoma; Chemotherapy; Morrow Assessment of Nausea and Emesis; Postchemotherapy emesis; Postchemotherapy nausea

Indexed keywords

AMITRIPTYLINE PLUS PERPHENAZINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; DOLASETRON MESILATE; DOXORUBICIN; FLUOROURACIL; GRANISETRON; LORAZEPAM; METHOTREXATE; ONDANSETRON; PERPHENAZINE; PHENOTHIAZINE; PROCHLORPERAZINE MALEATE; SEROTONIN 3 ANTAGONIST; THIETHYLPERAZINE; THIETHYLPERAZINE MALEATE; TROPISETRON; SEROTONIN ANTAGONIST;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; BREAST TUMOR; CARCINOMA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING, ANTICIPATORY;

EID: 0033153758     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19990701)86:1<64::aid-cncr11>3.0.co;2-%23     Document Type: Article

References (32)

1. Ettinger DS, Huber S, Kris MG, Levy M, McNulty R, Noonan KR, et al. NCCN proceedings. NCCN antiemesis practice guidelines. Oncology (Huntington) 1997;11:57-89.
2. de Mulder PHM, Seynaeve C, Vermorken JD, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:834-40.
3. Marty M, Pouillart P, Scholl S, Droz JP, zab M, Brion N, et al. Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-21.
4. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:1174-8.
5. Navari RM, Gandara DR, Hesketh PJ, Hall S, Mailliard J, Ritter H, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-8.
6. Stewart A, McQuade B, Cronje JDE, Goedhals L, Gudgeon A, Corette L, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomized, parallel-group study. Oncology (Huntington) 1935;52:202-10.
7. Jantunen IT, Flander MK, Heikkinen MI, Kuoppala TA, Teerenhovi L, Kataja W. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. Acta Oncol 1993;32:413-5.
8. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994;12:1045-9.
9. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994;12:2204-10.
10. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995;76:343-57.
11. 3 antagonist prophylaxis is not maintained. J Clin Oncol 1996;14:644-51.
12. Cunningham D, Hill M, Dicato M, Verweij J, Crombez R, de Mulder PHM, et al. Optimal antiemetic therapy for cisplatin-induced emesis over repeat courses [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:449.
13. Del Favero A, Ballatori E, Olivieri A, Tonato M, Roila F. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993;11:2396-404.
14. Hainsworth JD. The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 1992;19:48-52.
15. Morrow GR. A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow Assessment of Nausea and Emesis (MANE). Br J Cancer 1992;19(Suppl):S72-4.
16. Carnrike CLM, Brantley PJ, Bruce B, Faruqui S, Gresham FM, Buss RR, et al. Test-retest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy-related nausea and vomiting. J Psychopathol Behav Assess 1988;10: 107-16.
17. Hesketh PJ. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. Semin Oncol 1992;19:33-40.
18. Morrow GR. Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy. Cancer Treat Rep 1984; 68:1177-8.
19. Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985;55: 2766-70.
20. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170-6.
21. Morrow GR, Dobkin PL. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions. Clin Psychol Rev 1988;8:517-56.
22. Morrow GR, Lindke J, Black PM. Anticipatory nausea development in cancer patients: replication and extension of a learning model. Br J Psychol 1991;82:61-72.
23. Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Sympt Manage 1991;6:215-23.
24. Hesketh PJ, Kris MG, Grunberg SM, Beck AT, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
25. Hesketh PJ, Beck TM, Uhlenhopp M, Kris MG, Hainsworth JD, Harker WG, et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol 1995;13: 2117-22.
26. Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, et al. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1996;2:85-90.
27. Soukop M, McQuade B, Hunter E, Stewart A, Kaye SB, Cassidy J, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology (Huntington) 1992;49:295-304.
28. Clavel M, Soukop M, Greenstreet YL. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology (Huntington) 1993;50:180-5.
29. Levitt M, Warr D, Yelle L, Rayner HL, Lofters W, Perrault DJ, et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993;325(15):1081-4.
30. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993;328: 1076-80.
31. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997; 5:307-13.
32. 3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1993;29A: 51-6.